Future research should focus on understanding the spatiotemporal dynamics of IL6 during tumor progression and identifying patient subgroups that would benefit most from IL6-targeted therapies, especially in combination with immune checkpoint inhibitors. This evidence concerns the gene IL6 and neoplasm.